What is Lifesci Capital’s Estimate for AURA FY2024 Earnings?

Aura Biosciences, Inc. (NASDAQ:AURA) – Lifesci Capital issued their FY2024 earnings per share (EPS) estimates for shares of Aura Biosciences in a note issued to investors on Tuesday, January 21st. Lifesci Capital analyst O. Mccammon anticipates that the company will post earnings of ($1.65) per share for the year. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.67) per share. Lifesci Capital also issued estimates for Aura Biosciences’ Q4 2024 earnings at ($0.42) EPS and FY2025 earnings at ($2.52) EPS.

A number of other research analysts have also commented on AURA. Scotiabank increased their price objective on Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a research report on Friday, October 18th. Cowen reiterated a “buy” rating on shares of Aura Biosciences in a research report on Friday, October 18th. HC Wainwright restated a “buy” rating and set a $22.00 target price on shares of Aura Biosciences in a research report on Thursday, November 14th. Finally, BTIG Research lifted their price target on shares of Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a research report on Friday, October 18th. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Aura Biosciences has an average rating of “Buy” and a consensus target price of $23.00.

Aura Biosciences Price Performance

AURA opened at $7.89 on Friday. The stock has a market capitalization of $394.11 million, a P/E ratio of -4.56 and a beta of 0.30. The company’s 50 day simple moving average is $8.38 and its 200-day simple moving average is $8.91. Aura Biosciences has a one year low of $6.63 and a one year high of $12.38.

Aura Biosciences (NASDAQ:AURA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.42) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.02.

Institutional Investors Weigh In On Aura Biosciences

Several institutional investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Aura Biosciences in the 4th quarter valued at about $87,000. JPMorgan Chase & Co. raised its position in Aura Biosciences by 107.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 53,502 shares of the company’s stock valued at $477,000 after buying an additional 27,718 shares during the last quarter. Franklin Resources Inc. raised its position in Aura Biosciences by 14.8% in the 3rd quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company’s stock valued at $15,571,000 after buying an additional 215,597 shares during the last quarter. Barclays PLC lifted its stake in Aura Biosciences by 256.5% in the 3rd quarter. Barclays PLC now owns 61,010 shares of the company’s stock valued at $544,000 after acquiring an additional 43,897 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in Aura Biosciences by 4.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company’s stock worth $8,990,000 after acquiring an additional 39,379 shares during the last quarter. 96.75% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Aura Biosciences news, insider Janet Jill Hopkins sold 11,822 shares of Aura Biosciences stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $9.36, for a total value of $110,653.92. Following the transaction, the insider now owns 151,693 shares of the company’s stock, valued at approximately $1,419,846.48. The trade was a 7.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Los Pinos Elisabet De sold 15,955 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total transaction of $122,374.85. Following the sale, the insider now directly owns 304,692 shares of the company’s stock, valued at $2,336,987.64. This represents a 4.98 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 38,531 shares of company stock worth $345,454. Company insiders own 5.40% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.